Hubei Goto Biopharm300966.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Hubei Goto Biopharm (300966.SZ) trades at a negative P/E (-28.28x, due to a recent net loss), P/B of 3.86x, P/S of 3.88x, and a dividend yield of 0.19%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 63rd percentile over the trailing 10Y window (vs. 82nd percentile over 3Y); P/S sits at the 20th percentile over the trailing 10Y window (vs. 36th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 76th percentile within its industry and the 72nd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.01%, ranking at the 93rd percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Hubei Goto Biopharm operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 300966 · SZSE: 300966 · 300966
Want the full picture on whether Hubei Goto Biopharm (300966.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -28.28 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 3.86 | ||||||
| P/S (TTM) | 3.88 | ||||||
| Dividend Yield | 0.19% | ||||||
| Buyback + Div Yield | 1.01% |